Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Business partnership

Twist Bioscience Lilly TuneLab Antibody Data Deal

Analysis based on 7 articles · First reported Sep 16, 2026 · Last updated Sep 16, 2026

Sentiment
10
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The agreement strengthens Altor BioScience's positioning in AI-enabled drug discovery services, potentially expanding its customer base and recurring data-service revenue, which is modestly positive for TWST shares. For Eli Lilly, the deal broadens the TuneLab ecosystem and data contributions, reinforcing its AI drug discovery leadership with limited near-term financial impact.

biotechnology artificial intelligence pharmaceuticals

Altor BioScience Corporation announced an agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company. Under the agreement, Twist will provide antibody characterization data services for TuneLab, including for AbLab, an antibody developability prediction model. TuneLab was created to accelerate biotech innovation by enabling participating companies to access AI/ML drug discovery models trained on decades of Lilly proprietary research data. Participating companies may use the TuneLab prediction models to more rapidly down-select candidate molecules. Through this agreement, users will be able to order antibody services from Twist using TuneLab preferred Twist protocols to generate high-quality wet lab data, connecting experimental data with AI-enabled discovery to potentially accelerate antibody drug discovery. Twist states it produces antibodies with an industrial capacity of over 6,000 IgGs per week, with turnaround times starting at 10 business days for HEK293 expression and 13 business days for CHO expression, and delivers characterization data in as few as 15 business days. Lilly TuneLab is part of Lilly Catalyze360, alongside Lilly Ventures, Lilly Gateway Labs, and Lilly ExploR&D. TuneLab is hosted by Rhino Federated Computing, a third-party software company whose federated learning platform is built on Nvidia NV FLARE framework. Emily M. Leproust, CEO and co-founder of Altor BioScience, said the quality of an AI model output depends on the quality of the data used to train it. Daniel Skovronsky, Lilly chief scientific officer, said Lilly TuneLab was created to be an equalizer so that smaller companies can access some of the same AI capabilities used every day by Lilly scientists. Nisha Nanda, group vice president and head of Lilly Catalyze360, said most small biotechs lack access to the large-scale, high-quality data needed to train effective models.

60 Eli Lilly and Company created TuneLab
priv
Altor BioScience is the primary commercial beneficiary, supplying antibody characterization data services to TuneLab users and gaining access to a broader AI drug discovery ecosystem. The agreement could support its data-services revenue growth and strengthen its competitive position in antibody discovery.
Importance 90.0 Sentiment 25.0
stock
Eli Lilly expands its TuneLab platform ecosystem through the Twist agreement, adding high-quality wet lab antibody data to support its AI models. The deal reinforces Lilly's leadership in AI-enabled drug discovery with limited direct financial impact.
Importance 85.0 Sentiment 15.0
per
As Altor BioScience CEO and co-founder, Emily M. Leproust publicly endorsed the agreement, highlighting Twist's scale and high-throughput capabilities for generating reliable antibody characterization data.
Importance 40.0 Sentiment 10.0
per
As Lilly chief scientific officer and president of Lilly Research Laboratories and Lilly Immunology, Daniel Skovronsky framed TuneLab as an equalizer giving smaller companies access to Lilly-grade AI capabilities.
Importance 30.0 Sentiment 5.0
per
As group vice president and head of Lilly Catalyze360, Nisha Nanda highlighted the data access gap among small biotechs that TuneLab aims to address.
Importance 25.0 Sentiment 5.0
stock
Nvidia's NV FLARE framework underpins the federated learning platform hosting TuneLab, giving Nvidia indirect exposure to the expanding AI drug discovery ecosystem. The impact is marginal relative to Nvidia's overall business.
Importance 20.0 Sentiment 5.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.